Alexion’s Strensiq gets approval in Japan to treat hypophosphatasia
Strensiq (asfotase alfa), a bone-targeted enzyme replacement therapy, is the first such treatment to be approved in Japan for HPP patients. The company intends to start commercial treatment
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.